Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Mucositis 3Hematologic Neoplasms 3Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Multiple Myeloma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Graft vs Host Disease 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

Tacrolimus 38Cyclophosphamide 27Methotrexate 26Mycophenolic Acid 21Cyclosporine 21Busulfan 21fludarabine phosphate 20Antilymphocyte Serum 20Melphalan 15fludarabine 13Sirolimus 13Methylprednisolone 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 10thymoglobulin 9Stem Cell Transplantation 8Radiotherapy 7ruxolitinib 6Thiotepa 6Rituximab 6Granulocyte Colony-Stimulating Factor 6Prednisone 5Hematopoietic Stem Cell Transplantation 5Filgrastim 5Alemtuzumab 5Transplantation 4Etoposide 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Pentostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Graft vs Host Disease × angiotensin I (1-7) × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡